Modifi Biosciences Acquired by Merck Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi […] October 23, 2024
BTIF Portfolio Company, Kiyatec, Announces Publication of Study on 3D Predict™ Glioma in High-Grade Glioma (HGG) Patients New study demonstrates significant improvement in survival outcomes using Kiyatec’s 3D Predict Glioma test. Kiyatec, leaders in functional precision oncology, announced the publication of a pivotal study in Scientific Reports highlighting the impact of the 3D Predict Glioma test on improving survival outcomes for patients with HGG. The study, titled “Functional prediction of response to therapy prior to therapeutic […] September 11, 2024
EnClear Therapies, Inc. Secures Additional Funding to Advance Neuro-Oncology Innovations Support from the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, and Sontag Innovation Fund Strengthens Efforts in Pre-Clinical Development. EnClear Therapies, Inc., an early-stage neurotechnology innovator, is excited to announce the successful closing of its latest financing round. In this round, EnClear has expanded its neuro-oncology-focused funding base with investments […] September 4, 2024
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma MimiVax, Inc., a biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, today announced new investments from the venture philanthropy arms of leading brain tumor patient organizations, VC, private and existing investors. The investments from the Brain Tumor Investment Fund (BTIF), an affiliate of the National Brain Tumor Society (NBTS), […] January 9, 2024
Cordance Medical and EXACT Therapeutics Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain Cordance Medical, a leading innovator in non-invasive opening of the blood-brain barrier (BBB), and EXACT Therapeutics, a clinical-stage Norwegian biopharmaceutical precision health company developing Acoustic Cluster Therapy (ACT®), today announced a strategic partnership aimed at combining their breakthrough technologies to revolutionize drug delivery in the treatment of brain diseases. Cordance Medical’s NeuroAccess™ platform is designed […] September 7, 2023